When I'm not supporting public charter schools in the area of finance and accounting, building my non-profit (Black Dad Connection), publishing a book, designing a website, performing weddings, and just generally keeping busy as a father and husband I am, well, doing other things. For instance I read, play with toys, and generally don't sleep. [...]
There has been a lot of discussion about a number of “on the horizon” drugs that are designed to aggressively treat advanced prostate cancer, including MDV3100. MDV3100 is supposed to act as a “super” antiandrogen (Casodex is the currently most used antiandrogen in the treatment of advanced prostate cancer). You may qualify to participate in [...]
The use of Ketoconazole (Keto) in men with advanced prostate cancer is not considered mainstream, however there is clear evidence that it does reduce PSA in men with castrate resistant prostate cancer. Currently, most men with advanced prostate cancer who do use Keto utilize it prior to chemotherapy. There has been little literature evaluating the [...]
We all have only the present time. Our past and our future are only thoughts in our mind. Make good use of the present so that the thoughts of the past are happy and the thoughts of the future are full of hope and expectation. Joel
In July the Department of Veterans Affairs (VA) sent out the first stipend payments to nearly 100 family caregivers of veterans, including men with prostate cancer. To qualify for the benefits the caregivers first had to complete a training program, “Comprehensive Assistance for Family Caregivers”. Qualified family caregivers receive an average $1,600 in monthly stipend [...]
Amgen has submitted a supplemental Biologics License Application (sBLA) to the FDA to expand the indication for denosumab (XGEVA) its RANK ligand inhibitor to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. Although some doctors have already begun to use Xgeva in men with advanced prostate cancer, it is [...]
There is some good news; the New York State Legislature has passed the Oral Chemotherapy Equity Bill. However, before this bill can become law we have to have Governor Cuomo sign it, we need all of our New York Residents to contact the governor and ask that he signs it. […]
Amgen has submitted a supplemental Biologics License Application (sBLA) to the FDA to expand the indication for denosumab (XGEVA) its RANK ligand inhibitor to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, denosumab would be the first therapy licensed to prevent or delay the spread of cancer [...]
Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VENICE clinical trial evaluating the investigational agent Zaltrap (aflibercept) in the first-line treatment of men with castrate resistant prostate cancer will continue to completion as planned. They have not been asked to make any modifications due to efficacy or to safety concerns. This decision is based on [...]
My recent Letter to the Editor of the New York Times in response to the Op-Ed piece decrying the cost of cancer treatments: Your recent editorial about the high cost of cancer drugs missed a number of very significant points which must be considered. Yes, newly developed cancer drugs are expensive, but when treatments like [...]
